US4778054A - Pack for administering medicaments to patients - Google Patents
Pack for administering medicaments to patients Download PDFInfo
- Publication number
- US4778054A US4778054A US06/936,148 US93614886A US4778054A US 4778054 A US4778054 A US 4778054A US 93614886 A US93614886 A US 93614886A US 4778054 A US4778054 A US 4778054A
- Authority
- US
- United States
- Prior art keywords
- pack
- container
- powder
- medicament
- blister
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6081—Colour codes
Definitions
- This invention relates to a medicament-containing pack for use in a device by means of which the medicament can be administered to or by patients inhaling through the device.
- the medicament is in powder form.
- Devices are now quite well known for administering medicaments contained in capsules to patients suffering from bronchial conditions such as, for example, bronchial asthma. It is well known for medicament in powder or other finely divided form to be supplied in capsules which are loaded by a patient into such a device. The medicament is then released from the capsule and inhaled by the patient, usually through the mouth, but sometimes through the nose.
- capsules which are made of gelatin
- Gelatin is relatively unstable and is lacking in physical strength so that the capsules need to be protected by packaging, for example in glass bottles.
- Environmental degradation of both the capsules and their contents may occur in a relatively short time.
- An object of the present invention is to provide a more convenient way of administering medicament to such patients than has been possible hitherto and which avoids the need to pack medicaments in capsules.
- the present invention preferably makes use of the technique of packing medicaments by loading them in blister packs, that is to say packs comprising a-sheet, which may be laminated, of foil or plastics material which acts as a carrier and which is provided with a number of breakable or openable containers called "blisters" incorporating a sheet secured on a first sheet to form a cover or lid.
- blister packs are in common use with tablets of one kind or another, but we have discovered that they can also be used with medicaments in powder form.
- a pack comprising a circular carrier disc which has a plurality of pre-filled, hermetically sealed containers formed integrally therewith and arranged in a circle, each container containing directly a dose of medicament in the form of a powder, each container being puncturable to form a hole on each side thereof to allow air to flow through the container to entrain the powder contained therein.
- the invention is suitable for administering a variety of medicaments such as, for example, salbutamol, beclomethasone dipropionate and sodium cromoglycate.
- FIG. 1 is an exploded perspective view of a first embodiment of the device
- FIG. 2 is a detailed view of a plunger device of the same device
- FIG. 3 is an elevation of another embodiment of the device
- FIG. 4 is an exploded view of the embodiment illustrated in FIG. 3;
- FIG. 5 is a perspective view of yet another device
- FIG. 6 is a plan view of a blister pack according to the invention.
- FIG. 7 is a vertical section through a single blister, before puncturing
- FIGS. 8 and 9 are vertical sections, not to scale, through part of two packs according to the invention, showing examples of materials which may be used;
- FIGS. 10 and 11 are vertical sections, on an enlarged scale, showing blisters after puncturing, in which powder has been trapped;
- FIGS. 12a and 12b are vertical sections, on an enlarged scale showing a blister before and after puncturing.
- FIG. 13 is a vertical section, on an enlarged scale, showing a blister filled to two different extents with powder.
- FIGS. 1 and 2 of the drawings comprises a shallow cylindrical housing 1 of a plastics material which has a cylindrical chamber 2 therein.
- the chamber is closed at one end 3, herein considered the bottom of the chamber, and a removable cover 4 is a close fit over the chamber at the other end.
- a mouthpiece outlet 5 projects outwardly from the cylindrical wall of the housing 1 and communicates with the interior of the chamber 2.
- a perforated guard is provided in the mouthpiece to prevent any solid particles of an undesirably large size being inhaled by a patient inhaling through the mouthpiece.
- a rim or shoulder 6 runs round the inside wall of the chamber 2 to provide an annular support on which a blister pack 7 may be located.
- the blister pack has a plurality of puncturable containers or "blisters" 8 arranged in a circle.
- the blisters 8 are filled with medicament in the form of a powder.
- the blister pack is of circular disc form, and is removably fitted inside the chamber so that it is replaceable when the individual doses of medicament contained in the blisters have been discharged.
- the blister pack 7 is preferably a circular disc of foil laminate material with blisters or containers 8. Further details of the blister pack are given in the ensuing description.
- the chamber 2 contains a central open cylindrical support column 9 upstanding from the bottom wall 3 of the chamber.
- a clamp disc member 10 is removably fitted inside the chamber 2 and is rotatable therein. In use, the clamp member is placed on top of a blister pack 7 which has already been loaded into the chamber and is located on the support shoulder 6.
- the clamp member 10 has a plurality of apertures 11 which are arranged in a circle and so spaced from each other that each of them will receive one of the blisters 8 of the blister pack 7.
- a knob 12 is upstanding from the clamp member 10 and when the lid 4 is fitted on the housing 1 the knob 12 will project through an aperture 13 in the top of the lid 4. This knob can be turned by the patient to rotate the clamp member 10 and since the blisters 8 of the blister pack 7 are located in the apertures 11 in the clamp plate 10 rotation of the clamp member will also rotate the blister pack.
- a plurality of protuberances or pips 14 are provided on the top of the clamp member 10 and engage in a recess 15, FIG. 2, on the underside of the cover 4 to make sure that the clamp plate is correctly aligned in position. As will be seen, the knob 12 is fluted to provide a better grip for the patient.
- the cover 4 also has an aperture 16 in which a plunger 17 contained in a plunger housing 18 can be received.
- the plunger has an annular shoulder 19 and a spring 20 can bear between the shoulder 19 and the bottom of the plunger housing 18 to urge the plunger into an upper or inoperative position.
- the plunger may be provided with a knife edge 21 or other means to enable the blister to be punctured more easily.
- the plunger it is not essential that the plunger have a knife 21 to puncture the blister. If desired a needle can be used to puncture the blister or the plunger may have a pointed end or even a blunt end or any other convenient puncturing means may be used.
- the mouthpiece cover can have a locking member (not shown) which can be engaged with the plunger when the device is not in use to prevent accidental actuation of the plunger.
- the patient needing a dose of medicament may hold the device with the mouthpiece in his mouth.
- the patient then depresses the plunger to puncture the blister and give access to the medicament therefrom and inhales through the mouthpiece so that the medicament will be entrained in the air flow and will enter the lungs of the patient.
- the mouthpiece can be provided with air inlet slots 25 to modify the air flow as the patient inhales.
- the underside of the blister pack can be supported on another clamp plate instead of the support rim or shoulder 6.
- the blister pack is conveniently arranged to provide a sufficient number of individual doses for a patient for use during a convenient period such as one day or more.
- the housing can be modified by providing an additional chamber, not visible, at the bottom, this additional chamber being closed by a removable cover 26. This additional chamber can be used to store replacement blister packs.
- the mouthpiece may, if desired, be arranged so that a patient may use it to inhale through the nose.
- FIGS. 3 and 4 A modified device which does not use the clamp member 10 is illustrated in FIGS. 3 and 4.
- the device of this modification comprises a housing 30 having a chamber 31 therein.
- a mouthpiece 32 projects outwardly from the cylindrical wall of the housing 30 in a generally radial direction and communicates with the interior of the chamber 31.
- a perforated guard 33 is provided at the entrance to the mouthpiece 32.
- a rim or shoulder 34 runs round the inside wall of the chamber 31 to provide an annular support for a support member 35 in the form of a circular plate or disc.
- This support member is arranged to receive a blister pack 36.
- the blister pack 36 has a plurality of puncturable containers 37 arranged-in a circular row.
- These containers are in the form of "blisters" of a generally conical form and contain a medicament as described with reference to FIG. 1.
- the support member 35 has a plurality of holes 38 equal in number to the number of blisters 37 of the blister pack 36.
- the conical portion of one blister 37 is located in each of the holes 38 when the device is loaded and in use.
- An external rotatable member 39 with a knurled edge 40 is located in face contact with the bottom of the housing 30.
- a spindle or the like 41 with radial projections 42 extends centrally from the support member 35 through a hole 43 in the bottom of the housing 30 and into an opening 44 of complementary shape in a spigot 45 of the member 39.
- a removable cover 46 fits on top of the housing 30.
- An opening 47 is provided in the cover 46 and engages a projection 48 in the housing 30 so as correctly to locate the cover.
- the cover 46 carries a bracket 49 on which a lever or trigger 50 is pivotally mounted.
- a plunger 51 is located on the lever or trigger 50 and extends through a hole 52 in the cover.
- a spring 53 is provided to bear between the trigger or lever 50 and the top of the cover 46 to urge the lever or trigger upwards.
- the hole 52 is so positioned that each hole 38 in the support member 35 will register with this hole as the support member 35 is rotated.
- the trigger 50 can be depressed so that its plunger 51, which may be in the form of a needle, will pierce through the blister 37 located in that hole (i.e. pierce the top and the bottom of the blister) thereby to permit powder to exit from the blister. Some powder will fall into a tray-like compartment 54 inside the chamber 31.
- the mouthpiece 32 can be enclosed in a mouthpiece cover or sheath 55 which has a channel-like extension 56 which will engage with the bracket 49 to prevent the plunger 51 being depressed to enter through the hole 37.
- FIG. 5 illustrates a modified device which can conveniently be used to administer two different medicaments to a patient at separate times. Treatment of certain patients does require that they inhale two different kinds of medicament.
- a common housing 57 contains two chambers equivalent to the chamber 2 of the embodiment illustrated in FIGS. 1 and 2 or to the chamber 31 of the embodiment illustrated in FIGS. 3 and 4. These two chambers are enclosed by removable covers 58 and blister packs contained in the chambers can be rotated in the manner previously described by rotation of knurled wheels, knobs or other members 59.
- Outlet mouthpieces 60 project outwardly from the common housing 57, each one of these outlets 60 leading into one of the chambers enclosed by the common housing.
- Trigger mechanisms 61 are provided to enable the blisters of the blister packs contained in the chambers to be pierced so that the contents thereof can be inhaled by the patient.
- FIGS. 6 and 7 show a blister pack 90 which is circular in plan view, and has a plurality of blisters 91, in this case eight such blisters, to contain powdered medicament.
- the blisters are each circular in plan view and are arranged in a circle, so as to give a blister pack of the same general appearances as the blister pack 7 in FIG. 1 and the blister pack 36 in FIG. 4.
- Each blister has a diameter D and a depth d. The values which D and d should have are discussed further below.
- the diameter of the blister pack itself in this case is 54 mm.
- the smallest distance between adjacent blisters and between any given blister and the outer edge of the blister pack is preferably at least 3 mm in order to provide an adequate seal between the base and lid film which form the blister pack (see below).
- the blister pack 90 is formed from a base laminate to which is secured a lid laminate in which the blisters 91 are formed.
- the example shown in FIG. 8 comprises a base laminate 100, and a lid laminate 110 in which are formed the blisters 91 of which part of one is shown.
- the blisters each contain powdered medicament 112.
- the base laminate comprises three principal layers, namely a layer 101 of polyvinyl chloride 100 microns thick which forms one internal surface of each of the blisters and must thus be inert to the medicament 112, a layer 102 of aluminum foil 40 microns thick, and a layer 103 of biaxially oriented polyamide 25 microns thick.
- the layers are secured to one another by layers of adhesive 104 and 105.
- a fourth principal layer 106 may be added, namely a further layer of biaxially oriented polyamide 20 microns thick. This is secured to the layer 103 by an adhesive layer 107.
- the lid laminate 110 comprises a layer 118 of heat seal lacquer applied at a rate of 9 g/m 2 which forms an internal surface of each of the blisters and must thus be inert with respect to the medicament 112, a layer 114 of aluminum 25 microns thick and a layer 115 of a polyester lacquer applied at a rate of 2-10 g/m 2 .
- the lacquer layer 115 can be coloured, for decorative purposes and/or to assist the patient in identifying the medicament, and can also carry printing, for example further identification and/or instructions for use.
- the base and lid laminates are impermeable to light, air water and water vapor, and microorganisms, and the heat seal which the lacquer layer 113 forms with the PVC layer 101 is likewise impermeable, so that the medicament 112 is completely protected.
- FIG. 9 shows alternative materials which may be used.
- the blister pack of FIG. 9 comprises a base laminate 120 and a lid laminate 130.
- the base laminate comprises a polyethylene layer 121 applied at a rate of 20 g/m 2 and an aluminum layer 122 which is 20 microns thick. In the manufacture of the base laminate the polyethylene is extruded on to the aluminum.
- the base laminate 120 further comprises a layer 123 of oriented polyamide 25 microns thick secured to the layer 122 by an adhesive layer 124.
- the lid laminate 180 which is heat sealed to the base laminate, comprises a layer 181 of polyethylene applied at a rate of 15 g/m 2 extruded on to a layer 132 of aluminum 25 microns thick, and a layer 133 of polyester lacquer applied at a rate of 2-10 gm/m 2 .
- the lacquer layer 188 serves the same purpose as the lacquer layer 115 in the embodiment of FIG. 8.
- the embodiment of FIG. 9 has basically the same impermeability characteristics as those of FIG. 8.
- laminates shown in FIGS. 8 and 9 are examples only of structures which may be used in the present invention.
- Laminates of the type shown in FIGS. 8 and 9 are available from Aluminum-Walzwerke Singen GmbH of Alusingen-Platz 1, D-7700 Singen/Hohentwiel, West Germany.
- One feature of the embodiments of FIGS. 8 and 9 is that they are relatively rigid, which helps to avoid them being damaged and makes it easier to use them in the devices shown in FIGS. 1 to 5.
- the powdered medicament in the blisters preferably has a particle size range of from 0.5 to 10 microns.
- the medicament may comprise a pharmacologically active substance, such as one or more of those mentioned above, with a pharmaceutically acceptable carrier, such as lactose or starch, in powder form.
- the total amount of medicament present in each blister is preferably from 20-50 mg.
- This quantity of powder is such that it can be inhaled by an adult patient by a single inhalation.
- the internal volume of each blister is preferably such that the medicament occupies only a relatively small proportion of the volume. The reason for this is to enable the blister to be emptied as completely as possible and as reproducibly as possible, the latter being important to ensure that the patient always receives substantially the same dose.
- this amount can be kept to as little as 10% of the original contents of the blister, or even less.
- FIG. 10 shows, after puncturing a blister 91 which was overfilled with medicament, i.e. the medicament occupied too great a proportion of the volume.
- the peripheral portion of the punctured cover has trapped some of the powder in an annular region 140.
- FIG. 11 shows powder entrapment produced by having a blister which is too shallow, i.e. the ratio of diameter to depth is too great.
- the peripheral portion of the punctured cover traps powder in an annular region 150.
- FIGS. 12a and 12b show a blister, before and after puncturing respectively, which is neither overfilled nor too shallow.
- no powder is shown trapped in the region 160 which corresponds to the regions 140 and 150. In practice, a little powder may be trapped even in this case, but the amount will be small compared to that in regions 140 and 150.
- FIG. 13 indicates the filling range which is preferred in order to reduce powder entrapment caused by the mechanism of FIG. 10, whilst at the same time having enough powder to give a reproducible dose.
- the right hand side of FIG. 13 indicates the maximum degree of filling which may be used without significant powder entrapment.
- the internal depth of the blister (d in FIG. 7) is 4.5 mm and its volume is 0.2 cm 3 .
- the blister contains 40 mg of powder having a bulk density of 0.5 and thus occupying a volume of 0.08 cm 3 (40% of the blister volume).
- the clearance c between the upper surface of the powder and the blister cover is 2.8mm, i.e. the depth of the powder is approximately half the depth of the blister.
- the blister contains 25 mg of powder occupying 0.5 cm 3 (25% of the blister volume), and the clearance c is 2.8 mm. As a practical matter there should preferably be at least 20 mg of powder.
- the ratio of blister diameter D to blister depth d (see FIG. 7) is preferably less than 4.5:1. Typical values which may desirably be used are in the region of 2.6:1 to 2.9 to 1. The ratio is preferably not less than 2.4:1 in order to avoid problems in forming the blisters. Values of D are typically about 11 to 12 mm, and values for d are typically about 3.8 to 4.5 mm.
- the generally conical shape of the blisters is advantageous in that it presents the medicament to the airflow through the punctured blister in such a way as to assist emptying by the airflow.
Abstract
Description
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8228887 | 1982-10-08 | ||
GB8228887 | 1982-10-08 | ||
GB838314307A GB8314307D0 (en) | 1983-05-24 | 1983-05-24 | Medical administration devices |
GB8314307 | 1983-05-24 | ||
US06/540,203 US4627432A (en) | 1982-10-08 | 1983-10-07 | Devices for administering medicaments to patients |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/540,203 Continuation-In-Part US4627432A (en) | 1982-10-08 | 1983-10-07 | Devices for administering medicaments to patients |
Publications (1)
Publication Number | Publication Date |
---|---|
US4778054A true US4778054A (en) | 1988-10-18 |
Family
ID=27261787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/936,148 Expired - Lifetime US4778054A (en) | 1982-10-08 | 1986-12-01 | Pack for administering medicaments to patients |
Country Status (1)
Country | Link |
---|---|
US (1) | US4778054A (en) |
Cited By (211)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009561A (en) * | 1989-08-18 | 1991-04-23 | Pharmacia Diagnostics Inc. | Reagent tablet dispenser |
US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
US5277328A (en) * | 1993-05-24 | 1994-01-11 | Tocco Gary A | Multiply compartmented cooler |
US5337740A (en) * | 1991-08-01 | 1994-08-16 | New England Pharmaceuticals, Inc. | Inhalation devices |
US5348158A (en) * | 1991-12-19 | 1994-09-20 | G. D. Searle & Co. | Dispenser pack for the successive dispensing of a drug |
US5356010A (en) * | 1993-01-21 | 1994-10-18 | Primary Delivery Systems, Inc. | Container with blister pack opener |
US5431283A (en) * | 1993-01-21 | 1995-07-11 | Primary Delivery Systems, Inc. | Blister pack opener-ejector |
US5464118A (en) * | 1993-08-11 | 1995-11-07 | Hoechst Aktiengesellschaft | Apparatus for removing solid medications from blister packs |
US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
WO1996033759A1 (en) * | 1995-04-24 | 1996-10-31 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
WO1998029098A1 (en) | 1996-12-31 | 1998-07-09 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
US5816404A (en) * | 1996-02-20 | 1998-10-06 | Seidler; David | Blister pack with built-in openers |
US5853101A (en) * | 1993-01-21 | 1998-12-29 | Primary Delivery Systems, Inc. | Blister pack opener |
US5857456A (en) * | 1996-06-10 | 1999-01-12 | Sarnoff Corporation | Inhaler apparatus with an electronic means for enhanced release of dry powders |
US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US5909822A (en) * | 1997-05-03 | 1999-06-08 | George; Donald C. | Pill dispenser employing a sealed pill carrier |
US5915560A (en) * | 1997-05-03 | 1999-06-29 | George; Donald C. | Compartmentalized pill dispenser |
US5921237A (en) * | 1995-04-24 | 1999-07-13 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US5964417A (en) * | 1996-11-20 | 1999-10-12 | Ing. Erich Pfeiffer Gmbh | Dispenser for discharging media |
US6089228A (en) * | 1994-09-21 | 2000-07-18 | Inhale Therapeutic Systems | Apparatus and methods for dispersing dry powder medicaments |
US6098835A (en) * | 1998-09-03 | 2000-08-08 | Valley Design Inc. | Child resistant pill rotating disk dispenser |
US6116238A (en) * | 1997-12-02 | 2000-09-12 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
WO2001085097A2 (en) * | 2000-05-10 | 2001-11-15 | Innovative Devices, Llc | Medicament container with same side airflow inlet and outlet and method of use |
US6367473B1 (en) * | 1997-02-08 | 2002-04-09 | Ing. Erich Pfeiffer Gmbh | Medium dispenser |
US6443307B1 (en) | 2000-01-25 | 2002-09-03 | Michael D. Burridge | Medication dispenser with an internal ejector |
US20020168322A1 (en) * | 1998-10-09 | 2002-11-14 | Andrew Clark | Flow resistance modulated aerosolized active agent delivery |
WO2002098495A1 (en) | 2001-06-07 | 2002-12-12 | Innovata Biomed Limited | Unit dosage powder container |
US6550477B1 (en) | 1995-08-02 | 2003-04-22 | Innovative Devices, Llc | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US20030075172A1 (en) * | 2001-10-19 | 2003-04-24 | Johnson Keith A. | Method and apparatus for dispensing inhalator medicament |
US6606992B1 (en) | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
WO2003080469A1 (en) * | 2002-03-19 | 2003-10-02 | Comar, Inc. | Rotatable compact case with non-removable pill package insert |
US20030185765A1 (en) * | 1992-07-08 | 2003-10-02 | Platz Robert M. | Composition for pulmonary administration comprising a drug and a hydrophobic amino acid |
WO2003095010A2 (en) * | 2002-05-10 | 2003-11-20 | Oriel Therapeutics, Inc. | Dry powder inhalers for use with piezoelectric polymer-driven delivery means, and associated blister package comprising a piezoelectric polymer material |
US6655379B2 (en) | 1998-03-16 | 2003-12-02 | Nektar Therapeutics | Aerosolized active agent delivery |
WO2003107397A2 (en) * | 2002-05-15 | 2003-12-24 | Glaxo Group Limited | Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging |
US20040000309A1 (en) * | 2002-06-18 | 2004-01-01 | William Alston | Flow regulator for aerosol drug delivery and methods |
US6672304B1 (en) | 1995-06-08 | 2004-01-06 | Innovative Devices, Llc | Inhalation actuated device for use with metered dose inhalers (MDIs) |
US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
US6681767B1 (en) | 1991-07-02 | 2004-01-27 | Nektar Therapeutics | Method and device for delivering aerosolized medicaments |
US20040050860A1 (en) * | 2002-05-10 | 2004-03-18 | Crowder Timothy M. | Apparatus, systems and related methods for dispensing and /or evaluating dry powders |
US6737045B2 (en) | 1994-03-07 | 2004-05-18 | Nektar Therapeutics | Methods and compositions for the pulmonary delivery insulin |
US20040118399A1 (en) * | 2002-12-18 | 2004-06-24 | Elan Pharmaceutical Technologies | Unit dose dry powder inhaler |
US20040153262A1 (en) * | 2002-05-10 | 2004-08-05 | Crowder Timothy M. | Dry powder dose filling systems and related methods |
US20040173211A1 (en) * | 2003-01-14 | 2004-09-09 | Boehringer Ingelheim International Gmbh | Powder inhaler |
US6810872B1 (en) * | 1999-12-10 | 2004-11-02 | Unisia Jecs Corporation | Inhalant medicator |
US20040237961A1 (en) * | 1995-06-08 | 2004-12-02 | Snow John Medlin | Inhalation actuated device for use with metered dose inhalers (MDIs) |
US20040250812A1 (en) * | 1990-03-02 | 2004-12-16 | Davies Michael Birsha | Inhalation device |
US6871647B2 (en) | 2001-09-19 | 2005-03-29 | Advent Pharmaceuticals Pty Ltd | Inhaler |
US6881200B2 (en) | 1993-04-08 | 2005-04-19 | Powderject Research Limited | Needleless syringe using super sonic gas flow for particle delivery |
US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US20050103678A1 (en) * | 2002-03-26 | 2005-05-19 | Clark Verna L. | Method for forming a laminate assembly and products formed thereby |
US20050143675A1 (en) * | 2003-12-31 | 2005-06-30 | Home Diagnostics, Inc. | Integrated diagnostic test system |
US6915802B1 (en) * | 1999-10-16 | 2005-07-12 | Smithkline Beecham Corporation | Medicament pack |
US20050154491A1 (en) * | 2002-01-25 | 2005-07-14 | Anderson Gregor J.M. | Medicament dispenser |
US20050161041A1 (en) * | 2000-05-16 | 2005-07-28 | Carlos Schuler | Systems devices and methods for opening receptacles having a powder to be fluidized |
US20050236420A1 (en) * | 2002-03-06 | 2005-10-27 | Reckitt Benckiser N.V. | Container |
US20050238708A1 (en) * | 2004-04-23 | 2005-10-27 | Andrew Jones | Sealed capsule including an integrated puncturing mechanism |
US20050251289A1 (en) * | 2002-07-25 | 2005-11-10 | Bonney Stanley G | Medicament dispenser |
US20050247312A1 (en) * | 2002-07-25 | 2005-11-10 | Davies Michael B | Medicament dispenser |
US20050256201A1 (en) * | 2002-04-25 | 2005-11-17 | Glaxo Group Limited | Phenethanolamine derivatives |
US20050268909A1 (en) * | 2002-07-25 | 2005-12-08 | Bonney Stanley G | Medicament dispenser |
US20050268908A1 (en) * | 2002-07-25 | 2005-12-08 | Bonney Stanley G | Medicament dispenser |
US20050274378A1 (en) * | 2002-07-25 | 2005-12-15 | Bonney Stanley G | Medicament dispenser |
US20050279349A1 (en) * | 1991-07-02 | 2005-12-22 | Patton John S | Method and device for delivering aerosolized medicaments |
US20060005398A1 (en) * | 2004-07-12 | 2006-01-12 | Steve Sramek | Device for removing a pharmaceutical dosage unit from a unit package |
US20060050765A1 (en) * | 2002-04-25 | 2006-03-09 | Walker Dwight S | Magnetoacoustic sensor system and associated method for sensing environmental conditions |
US20060076010A1 (en) * | 2002-12-18 | 2006-04-13 | King Michael L | Drug delivery system with vented mouthpiece |
US20060148771A1 (en) * | 2003-02-14 | 2006-07-06 | Keith Biggadike | Medicinal compounds |
US20060187750A1 (en) * | 2002-03-01 | 2006-08-24 | Victor Aldrich | Rotary blending apparatus and system |
US20060205790A1 (en) * | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
WO2006104889A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Novel compounds |
US20060237010A1 (en) * | 2003-06-16 | 2006-10-26 | Rijksuniversiteit Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
US7159720B2 (en) | 2004-03-18 | 2007-01-09 | Pearson Stephen J | Container having a rotatable ring |
US20070049641A1 (en) * | 2005-08-24 | 2007-03-01 | Rabindra Tirouvanziam | Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis |
US20070053843A1 (en) * | 2003-10-28 | 2007-03-08 | Dawson Michelle L | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
US20070066527A1 (en) * | 2005-09-07 | 2007-03-22 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US20070135490A1 (en) * | 2003-10-24 | 2007-06-14 | Keith Biggadike | Phenetanolamine derivatives |
US20070139442A1 (en) * | 2002-09-13 | 2007-06-21 | Robinson Karl E | Coated blending system |
US20070164029A1 (en) * | 2006-01-03 | 2007-07-19 | Gelardi John A | System for Opening an Article Encasement |
US20070172385A1 (en) * | 2003-12-17 | 2007-07-26 | Glaxo Group Limited | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders |
US7278419B2 (en) | 1993-01-29 | 2007-10-09 | Novo Nordisk A/S | Method for treating diabetes mellitus in a patient |
US20070267318A1 (en) * | 2002-08-29 | 2007-11-22 | Colbert Packaging Corporation | Dispensing Package |
US20070277820A1 (en) * | 2003-10-27 | 2007-12-06 | Timothy Crowder | Blister packages and associated methods of fabricating dry powder drug containment systems |
US20080042823A1 (en) * | 2004-11-12 | 2008-02-21 | Heasley Matthew G | Sensor System with Acoustic Transducer |
WO2008037519A1 (en) * | 2006-09-26 | 2008-04-03 | Alfred Von Schuckmann | Dispenser for powder compounds |
US20080108645A1 (en) * | 2004-02-11 | 2008-05-08 | Cambridge Laboratories, (Ireland), Ltd. | Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them |
US7377277B2 (en) | 2003-10-27 | 2008-05-27 | Oriel Therapeutics, Inc. | Blister packages with frames and associated methods of fabricating dry powder drug containment systems |
US20080125462A1 (en) * | 2005-01-11 | 2008-05-29 | Lois Elizabeth Vernon | Cinnamate Salts Of A Beta-2 Adrenergic Agonist |
US20080156816A1 (en) * | 2007-01-03 | 2008-07-03 | Gelardi John A | Container With Cutting Apparatus |
US20080197045A1 (en) * | 2005-07-27 | 2008-08-21 | Burkhard Metzger | Medicament Blister |
US20080223747A1 (en) * | 2002-08-29 | 2008-09-18 | Colbert Packaging Corporation | Childproof, senior-friendly blister pack |
US7428446B2 (en) | 2002-05-10 | 2008-09-23 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
WO2008118724A1 (en) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides as ikk2 inhibitors |
US20080237082A1 (en) * | 2007-03-29 | 2008-10-02 | R. P. Scherer Technologies, Inc. | Child resistant device for housing blister packs |
US7442839B2 (en) | 2002-10-28 | 2008-10-28 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
US7448375B2 (en) | 1993-01-29 | 2008-11-11 | Aradigm Corporation | Method of treating diabetes mellitus in a patient |
US7451761B2 (en) | 2003-10-27 | 2008-11-18 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US20080300535A1 (en) * | 2001-07-26 | 2008-12-04 | Powderject Research Limited | Particle cassette, method and kit therefor |
US20080319000A1 (en) * | 2005-07-14 | 2008-12-25 | Cambridge Laboratories (Ireland) Limited | Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease |
WO2009004456A1 (en) * | 2007-07-02 | 2009-01-08 | Pfizer Limited | Dry powder container and use of such dry powder container in a dry powder inhaler |
US20090029901A1 (en) * | 2005-02-10 | 2009-01-29 | Marian Wood-Kaczmar | Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations |
US20090029906A1 (en) * | 2005-04-29 | 2009-01-29 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US20090047351A1 (en) * | 2005-02-10 | 2009-02-19 | Stephen Newman | Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom |
US20090057186A1 (en) * | 2005-02-15 | 2009-03-05 | Willard Rick L | Pill packaging system |
US20090105309A1 (en) * | 2003-10-22 | 2009-04-23 | Glaxo Group Limited | Medicinal Compounds |
US20090149389A1 (en) * | 2007-01-10 | 2009-06-11 | Purdue Research Foundation | Kinase Inhibitors And Uses Thereof |
US20090192227A1 (en) * | 2005-08-24 | 2009-07-30 | Rabindra Tirouvanziam | N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease |
US20090196927A1 (en) * | 2007-01-10 | 2009-08-06 | Alyssa Panitch | Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor |
US20090194105A1 (en) * | 2006-04-13 | 2009-08-06 | Jens Besseler | Inhaler |
US20090230130A1 (en) * | 2003-06-09 | 2009-09-17 | John Gelardi | System for storing and unpacking encased article |
US20090275605A1 (en) * | 2005-08-05 | 2009-11-05 | Cambridge Laboratories (Ireland) Limited | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease |
US20090291894A1 (en) * | 2005-09-07 | 2009-11-26 | Nikolaos Tezapsidis | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
US20100055133A1 (en) * | 2008-08-12 | 2010-03-04 | Biovail Laboratories International (Barbados) S.R.L | Pharmaceutical compositions |
US20100063157A1 (en) * | 2004-04-02 | 2010-03-11 | Caine Darren Michael | Chemical process and new crystalline form |
US7677411B2 (en) | 2002-05-10 | 2010-03-16 | Oriel Therapeutics, Inc. | Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders |
WO2010036839A2 (en) * | 2008-09-26 | 2010-04-01 | Oriel Therapeutics, Inc. | Inhalers with airway disks having discrete airway channels and related disks and methods |
US20100087476A1 (en) * | 2008-09-08 | 2010-04-08 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compounds |
US20100087475A1 (en) * | 2008-09-08 | 2010-04-08 | Biovali Laboratories International (Barbados) S.R.L. | Pharmaceutical compounds |
US20100098760A1 (en) * | 2007-01-10 | 2010-04-22 | Alyssa Panitch | Polypeptide for treating or preventing adhesions |
US20100113358A1 (en) * | 2005-09-07 | 2010-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
US20100158968A1 (en) * | 2008-12-10 | 2010-06-24 | Alyssa Panitch | Cell-permeant peptide-based inhibitor of kinases |
US7744925B2 (en) | 1994-12-02 | 2010-06-29 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
CN101945682A (en) * | 2008-02-12 | 2011-01-12 | 阿斯利康(瑞典)有限公司 | Inhaler comprising a base having at least one sealed cavity containing medicament |
US20110052658A1 (en) * | 2009-07-27 | 2011-03-03 | Alyssa Panitch | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
US20110061652A1 (en) * | 2004-10-21 | 2011-03-17 | Boehringer Ingelheim International Gmbh | Blister for inhalers |
USD635246S1 (en) | 2010-03-26 | 2011-03-29 | Oriel Therapeutics, Inc. | Dose disk for dry powder inhalers |
US7956065B2 (en) | 2008-09-08 | 2011-06-07 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compounds |
USD641076S1 (en) | 2010-03-26 | 2011-07-05 | Oriel Therapeutics, Inc. | Dry powder inhaler |
US20110162648A1 (en) * | 2008-09-26 | 2011-07-07 | Ruckdeschel Thomas W | Inhaler mechanisms with radially biased piercers and related methods |
US20110174306A1 (en) * | 2008-09-30 | 2011-07-21 | David Harris | Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods |
US20110190217A1 (en) * | 2005-04-29 | 2011-08-04 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides |
US20110190333A1 (en) * | 2008-06-13 | 2011-08-04 | Biovail Laboratories International (Barbados) S.R.L. | Dihydrotetrabenanzine for the treatment of anxiety |
US20110186047A1 (en) * | 2008-10-01 | 2011-08-04 | Scott Alexander Lewis | Dry Powder Inhalers with Rotating Piercing Mechanisms and Related Devices and Methods |
US20110272427A1 (en) * | 2010-05-07 | 2011-11-10 | Fily Sebastien Lucien | Blister dispenser |
CN102303772A (en) * | 2011-06-22 | 2012-01-04 | 美的集团有限公司 | Automatic adding device for household appliance |
WO2012028662A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012028663A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2436686A1 (en) | 2005-03-25 | 2012-04-04 | Glaxo Group Limited | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator |
US20120241451A1 (en) * | 2011-03-24 | 2012-09-27 | Fred Pether | Tamper Device |
WO2012159103A1 (en) | 2011-05-19 | 2012-11-22 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
US8381721B2 (en) | 2008-09-26 | 2013-02-26 | Oriel Therapeutics, Inc. | Dry powder inhalers with dual piercing members and related devices and methods |
EP2589381A1 (en) | 2011-11-04 | 2013-05-08 | Rabindra Tirouvanziam | Compositions for improving or preserving lung function in a patient with a pulmonary disorder |
US20140001194A1 (en) * | 2012-06-29 | 2014-01-02 | R. J. Reynolds Tobacco Company | Dispensing container, packaged product assembly, and related method |
WO2014039533A2 (en) | 2012-09-04 | 2014-03-13 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
WO2014085474A1 (en) | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
US8802149B2 (en) | 1996-12-31 | 2014-08-12 | Novartis Pharma Ag | Systems and processes for spray drying hydrophobic and hydrophilic components |
US8875892B1 (en) | 2013-03-11 | 2014-11-04 | Dominique Warner | Multi-compartment ring-shaped holder |
WO2015038644A2 (en) | 2013-09-10 | 2015-03-19 | Debrabander Jef | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
WO2015097662A1 (en) * | 2013-12-23 | 2015-07-02 | Glenmark Pharmaceuticals Ltd | A dry powder inhaler |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
US9297813B2 (en) | 2010-11-11 | 2016-03-29 | Agency For Science, Technology And Research | Targeting metabolic enzymes in human cancer |
WO2016081475A1 (en) | 2014-11-17 | 2016-05-26 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
WO2016092378A1 (en) | 2014-12-10 | 2016-06-16 | Angelo Luigi Vescovi | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors |
WO2016142426A1 (en) | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
US9452218B2 (en) | 2012-03-09 | 2016-09-27 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
WO2016200694A1 (en) | 2015-06-10 | 2016-12-15 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
WO2016203400A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
WO2017011215A1 (en) | 2015-07-15 | 2017-01-19 | The Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
US9585932B2 (en) | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
US9642888B2 (en) | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
USD793356S1 (en) * | 2014-12-16 | 2017-08-01 | Musik, LLC | Headphone touchpad |
EP3202399A1 (en) | 2009-07-24 | 2017-08-09 | Amazetis SA | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
WO2018055527A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
WO2018055526A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
WO2018055524A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
US9999655B2 (en) | 2015-03-12 | 2018-06-19 | Moerae Matrix, Inc. | Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
WO2018109646A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 compounds |
WO2018109649A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as nrf2 regulators |
WO2018109648A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
US20180236188A1 (en) * | 2015-10-23 | 2018-08-23 | Arven Ilac Sanayi Ve Ticaret A.S. | Blister for inhalable formulation of tiotropium bromide |
US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
US10087225B2 (en) | 2015-01-08 | 2018-10-02 | Moerae Matrix, Inc. | Formulation of MK2 inhibitor peptides |
US10112948B2 (en) | 2015-07-06 | 2018-10-30 | The Board Of Regents Of The University Of Texas System | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers |
WO2018200425A1 (en) | 2017-04-24 | 2018-11-01 | Cocrystal Pharma, Inc. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
WO2019116230A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
WO2019115640A1 (en) | 2017-12-15 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | 6-(morpholin-4-yl)-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine derivatives as m-tor inhibitors |
US10328216B2 (en) | 2016-01-20 | 2019-06-25 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation |
US10336788B2 (en) | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
WO2019141694A1 (en) | 2018-01-17 | 2019-07-25 | Glaxosmithkline Intellectual Property Development Limited | Pi4kiiibeta inhibitors |
WO2019224667A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Indanes as nrf2 activators |
WO2020023813A1 (en) | 2018-07-27 | 2020-01-30 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |
WO2020055858A1 (en) | 2018-09-10 | 2020-03-19 | Cocrystal Pharma, Inc. | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication |
WO2020081751A1 (en) | 2018-10-17 | 2020-04-23 | Cocrystal Pharma, Inc. | Combinations of inhibitors of influenza virus replication |
WO2020102270A1 (en) | 2018-11-13 | 2020-05-22 | Cocrystal Pharma, Inc. | Formulations of influenza therapeutics |
WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
WO2020249652A1 (en) | 2019-06-13 | 2020-12-17 | Glaxosmithkline Intellectual Property Development Limited | Pyridyl or pyrimidyl mtor kinase inhibitors |
EP3782996A1 (en) | 2015-06-15 | 2021-02-24 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
WO2021188620A1 (en) | 2020-03-17 | 2021-09-23 | Cocrystal Pharma Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
WO2021206876A1 (en) | 2020-04-10 | 2021-10-14 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
WO2021216547A1 (en) | 2020-04-20 | 2021-10-28 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
WO2022179967A1 (en) | 2021-02-23 | 2022-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Vadadustat for treating covid-19 in a hospitalized subject |
WO2023014758A1 (en) | 2021-08-03 | 2023-02-09 | Cocrystal Pharma, Inc. | Inhibitors for coronaviruses |
US11833118B2 (en) | 2016-01-20 | 2023-12-05 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB516834A (en) * | 1937-12-23 | 1940-01-12 | Charles Alexandre Nicolle | Improvements in or relating to packaging |
GB925927A (en) * | 1960-07-05 | 1963-05-15 | American Cyanamid Co | Method and machine for manufacturing plastic granule-containing capsules |
GB1019963A (en) * | 1961-11-04 | 1966-02-09 | Bodet Jean Augustin | A package of pellets and apparatus for producing same |
GB1075679A (en) * | 1963-11-12 | 1967-07-12 | Ciba Ltd | Dispensing container for medicaments |
GB1387959A (en) * | 1972-06-21 | 1975-03-19 | Sic Schweizerische Ind Ges | Apparatus for dividing stacked articles into batches |
US4015717A (en) * | 1974-03-29 | 1977-04-05 | The Medical Dispenser Company | Tablet package for use in chronologically dispensing tablets |
US4074806A (en) * | 1977-02-18 | 1978-02-21 | Deena Packaging Industries, Inc. | Tablet dispensing container |
US4089415A (en) * | 1975-08-15 | 1978-05-16 | Laib Jakob C | Ampule |
US4298125A (en) * | 1980-05-19 | 1981-11-03 | Bristol-Myers Company | Dial type child resistant dispenser |
US4342395A (en) * | 1981-02-02 | 1982-08-03 | Brown James B | Liquid dispensing unit and method of manufacture thereof |
-
1986
- 1986-12-01 US US06/936,148 patent/US4778054A/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB516834A (en) * | 1937-12-23 | 1940-01-12 | Charles Alexandre Nicolle | Improvements in or relating to packaging |
GB925927A (en) * | 1960-07-05 | 1963-05-15 | American Cyanamid Co | Method and machine for manufacturing plastic granule-containing capsules |
GB1019963A (en) * | 1961-11-04 | 1966-02-09 | Bodet Jean Augustin | A package of pellets and apparatus for producing same |
GB1075679A (en) * | 1963-11-12 | 1967-07-12 | Ciba Ltd | Dispensing container for medicaments |
GB1387959A (en) * | 1972-06-21 | 1975-03-19 | Sic Schweizerische Ind Ges | Apparatus for dividing stacked articles into batches |
US4015717A (en) * | 1974-03-29 | 1977-04-05 | The Medical Dispenser Company | Tablet package for use in chronologically dispensing tablets |
US4089415A (en) * | 1975-08-15 | 1978-05-16 | Laib Jakob C | Ampule |
US4074806A (en) * | 1977-02-18 | 1978-02-21 | Deena Packaging Industries, Inc. | Tablet dispensing container |
US4298125A (en) * | 1980-05-19 | 1981-11-03 | Bristol-Myers Company | Dial type child resistant dispenser |
US4342395A (en) * | 1981-02-02 | 1982-08-03 | Brown James B | Liquid dispensing unit and method of manufacture thereof |
Cited By (345)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009561A (en) * | 1989-08-18 | 1991-04-23 | Pharmacia Diagnostics Inc. | Reagent tablet dispenser |
US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
USRE40045E1 (en) * | 1989-09-08 | 2008-02-05 | Glaxo Group Limited | Medicaments |
US20040250812A1 (en) * | 1990-03-02 | 2004-12-16 | Davies Michael Birsha | Inhalation device |
US7225808B2 (en) | 1990-03-02 | 2007-06-05 | Glaxo Group Limited | Inhalation device |
US20060107948A9 (en) * | 1990-03-02 | 2006-05-25 | Davies Michael B | Inhalation device |
US5492112A (en) * | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6681767B1 (en) | 1991-07-02 | 2004-01-27 | Nektar Therapeutics | Method and device for delivering aerosolized medicaments |
US20050279349A1 (en) * | 1991-07-02 | 2005-12-22 | Patton John S | Method and device for delivering aerosolized medicaments |
US5715810A (en) * | 1991-07-25 | 1998-02-10 | Sepracor Inc. | Inhalation devices |
US5337740A (en) * | 1991-08-01 | 1994-08-16 | New England Pharmaceuticals, Inc. | Inhalation devices |
US5529059A (en) * | 1991-08-01 | 1996-06-25 | Sepracor Inc. | Inhalation devices |
US5348158A (en) * | 1991-12-19 | 1994-09-20 | G. D. Searle & Co. | Dispenser pack for the successive dispensing of a drug |
US20030198601A1 (en) * | 1992-07-08 | 2003-10-23 | Platz Robert M. | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
US20030185765A1 (en) * | 1992-07-08 | 2003-10-02 | Platz Robert M. | Composition for pulmonary administration comprising a drug and a hydrophobic amino acid |
US6797258B2 (en) | 1992-07-08 | 2004-09-28 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized macromolecules |
US6921527B2 (en) | 1992-07-08 | 2005-07-26 | Nektar Therapeutics | Composition for pulmonary administration comprising a drug and a hydrophobic amino acid |
US5853101A (en) * | 1993-01-21 | 1998-12-29 | Primary Delivery Systems, Inc. | Blister pack opener |
US5431283A (en) * | 1993-01-21 | 1995-07-11 | Primary Delivery Systems, Inc. | Blister pack opener-ejector |
US5356010A (en) * | 1993-01-21 | 1994-10-18 | Primary Delivery Systems, Inc. | Container with blister pack opener |
US7278419B2 (en) | 1993-01-29 | 2007-10-09 | Novo Nordisk A/S | Method for treating diabetes mellitus in a patient |
US7448375B2 (en) | 1993-01-29 | 2008-11-11 | Aradigm Corporation | Method of treating diabetes mellitus in a patient |
US6881200B2 (en) | 1993-04-08 | 2005-04-19 | Powderject Research Limited | Needleless syringe using super sonic gas flow for particle delivery |
US7618394B2 (en) | 1993-04-08 | 2009-11-17 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
US20050165348A1 (en) * | 1993-04-08 | 2005-07-28 | Bellhouse Brian J. | Needleless syringe using supersonic gas flow for particle delivery |
US7942846B2 (en) | 1993-04-08 | 2011-05-17 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
US5277328A (en) * | 1993-05-24 | 1994-01-11 | Tocco Gary A | Multiply compartmented cooler |
US5464118A (en) * | 1993-08-11 | 1995-11-07 | Hoechst Aktiengesellschaft | Apparatus for removing solid medications from blister packs |
US6737045B2 (en) | 1994-03-07 | 2004-05-18 | Nektar Therapeutics | Methods and compositions for the pulmonary delivery insulin |
US7521069B2 (en) | 1994-03-07 | 2009-04-21 | Novartis Ag | Methods and compositions for pulmonary delivery of insulin |
US6543448B1 (en) | 1994-09-21 | 2003-04-08 | Inhale Therapeutic Systems, Inc. | Apparatus and methods for dispersing dry powder medicaments |
US6089228A (en) * | 1994-09-21 | 2000-07-18 | Inhale Therapeutic Systems | Apparatus and methods for dispersing dry powder medicaments |
US7785631B2 (en) | 1994-12-02 | 2010-08-31 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US7780991B2 (en) | 1994-12-02 | 2010-08-24 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US7744925B2 (en) | 1994-12-02 | 2010-06-29 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US7097827B2 (en) | 1995-04-14 | 2006-08-29 | Inhale Therapeutic Systems, Inc. | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
WO1996033759A1 (en) * | 1995-04-24 | 1996-10-31 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
EP0835147B1 (en) * | 1995-04-24 | 2004-01-28 | Valois SAS | Dry powder inhaler delivery system |
US6029663A (en) * | 1995-04-24 | 2000-02-29 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US5921237A (en) * | 1995-04-24 | 1999-07-13 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
EP0835147A1 (en) * | 1995-04-24 | 1998-04-15 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US5622166A (en) * | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US6672304B1 (en) | 1995-06-08 | 2004-01-06 | Innovative Devices, Llc | Inhalation actuated device for use with metered dose inhalers (MDIs) |
US6729324B2 (en) | 1995-06-08 | 2004-05-04 | Innovative Devices, Llc. | Inhalation actuated device for use with metered dose inhalers (MDIs) |
US20040237961A1 (en) * | 1995-06-08 | 2004-12-02 | Snow John Medlin | Inhalation actuated device for use with metered dose inhalers (MDIs) |
US6550477B1 (en) | 1995-08-02 | 2003-04-22 | Innovative Devices, Llc | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US6561186B2 (en) | 1995-08-02 | 2003-05-13 | Innovative Devices | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
US5816404A (en) * | 1996-02-20 | 1998-10-06 | Seidler; David | Blister pack with built-in openers |
US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US5857456A (en) * | 1996-06-10 | 1999-01-12 | Sarnoff Corporation | Inhaler apparatus with an electronic means for enhanced release of dry powders |
US6591833B2 (en) | 1996-06-10 | 2003-07-15 | Delsys Pharmaceutical Corp. | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US5964417A (en) * | 1996-11-20 | 1999-10-12 | Ing. Erich Pfeiffer Gmbh | Dispenser for discharging media |
WO1998029098A1 (en) | 1996-12-31 | 1998-07-09 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
US8802149B2 (en) | 1996-12-31 | 2014-08-12 | Novartis Pharma Ag | Systems and processes for spray drying hydrophobic and hydrophilic components |
US6367473B1 (en) * | 1997-02-08 | 2002-04-09 | Ing. Erich Pfeiffer Gmbh | Medium dispenser |
US5909822A (en) * | 1997-05-03 | 1999-06-08 | George; Donald C. | Pill dispenser employing a sealed pill carrier |
US5915560A (en) * | 1997-05-03 | 1999-06-29 | George; Donald C. | Compartmentalized pill dispenser |
US6116238A (en) * | 1997-12-02 | 2000-09-12 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US6655379B2 (en) | 1998-03-16 | 2003-12-02 | Nektar Therapeutics | Aerosolized active agent delivery |
US7422013B2 (en) | 1998-06-04 | 2008-09-09 | Nektar Therapeutics | Dry powder dispersing apparatus and methods for their use |
US20080230058A1 (en) * | 1998-06-04 | 2008-09-25 | Nektar Therapeutics | Dry powder dispersing apparatus and methods for their use |
US8161969B2 (en) | 1998-06-04 | 2012-04-24 | Novartis Ag | Dry powder dispersing apparatus and methods for their use |
US6257233B1 (en) | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
US20030209243A1 (en) * | 1998-06-04 | 2003-11-13 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
US6901929B2 (en) | 1998-06-04 | 2005-06-07 | Nektar Therapeutics | Dry powder dispersing apparatus and methods for their use |
US6546929B2 (en) | 1998-06-04 | 2003-04-15 | Inhale Therapeutic Systems, Inc. | Dry powder dispersing apparatus and methods for their use |
US6098835A (en) * | 1998-09-03 | 2000-08-08 | Valley Design Inc. | Child resistant pill rotating disk dispenser |
US8408200B2 (en) | 1998-10-09 | 2013-04-02 | Novartis Ag | Flow resistance modulated aerosolized active agent delivery |
US20020168322A1 (en) * | 1998-10-09 | 2002-11-14 | Andrew Clark | Flow resistance modulated aerosolized active agent delivery |
US6606992B1 (en) | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
US6915802B1 (en) * | 1999-10-16 | 2005-07-12 | Smithkline Beecham Corporation | Medicament pack |
US6810872B1 (en) * | 1999-12-10 | 2004-11-02 | Unisia Jecs Corporation | Inhalant medicator |
US20050048003A1 (en) * | 1999-12-10 | 2005-03-03 | Unisia Jecs Corporation | Inhalant medicator |
US6679256B2 (en) | 1999-12-17 | 2004-01-20 | Nektar Therapeutics | Systems and methods for extracting powders from receptacles |
US6443307B1 (en) | 2000-01-25 | 2002-09-03 | Michael D. Burridge | Medication dispenser with an internal ejector |
WO2001085097A3 (en) * | 2000-05-10 | 2002-07-25 | Innovative Devices Llc | Medicament container with same side airflow inlet and outlet and method of use |
US20020134382A1 (en) * | 2000-05-10 | 2002-09-26 | Snow John M. | Medicament container with same side airflow inlet and outlet and method of use |
WO2001085097A2 (en) * | 2000-05-10 | 2001-11-15 | Innovative Devices, Llc | Medicament container with same side airflow inlet and outlet and method of use |
EP1726324A1 (en) | 2000-05-10 | 2006-11-29 | Innovative Devices, LLC | Medicament container with same side airflow inlet and outlet |
US20050056281A1 (en) * | 2000-05-10 | 2005-03-17 | Snow John M. | Medicament container with same side airflow inlet and outlet and method of use |
JP2004508072A (en) * | 2000-05-10 | 2004-03-18 | イノベーティブ・ディバイシィーズ・エルエルシー | Drug container with airflow inlet and outlet on the same side, and method of using the container |
US7318436B2 (en) | 2000-05-10 | 2008-01-15 | Innovative Devices, Llc | Medicament container with same side airflow inlet and outlet and method of use |
EP1283731A2 (en) * | 2000-05-10 | 2003-02-19 | Innovative Devices, LLC | Medicament container with same side airflow inlet and outlet and method of use |
JP4754758B2 (en) * | 2000-05-10 | 2011-08-24 | イノベーティブ・ディバイシィーズ・エルエルシー | Drug container with air flow inlet and outlet on the same side |
US6923178B2 (en) | 2000-05-10 | 2005-08-02 | Innovative Devices, Llc. | Medicament container with same side airflow inlet and outlet |
EP1283731A4 (en) * | 2000-05-10 | 2004-06-23 | Innovative Devices Llc | Medicament container with same side airflow inlet and outlet and method of use |
US6948494B1 (en) | 2000-05-10 | 2005-09-27 | Innovative Devices, Llc. | Medicament container with same side airflow inlet and outlet and method of use |
AU2001249773B2 (en) * | 2000-05-10 | 2005-10-13 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Medicament container with same side airflow inlet and outlet and method of use |
US20050161041A1 (en) * | 2000-05-16 | 2005-07-28 | Carlos Schuler | Systems devices and methods for opening receptacles having a powder to be fluidized |
US7814905B2 (en) * | 2000-05-16 | 2010-10-19 | Novartis Ag | Systems devices and methods for opening receptacles having a powder to be fluidized |
US6669022B2 (en) * | 2001-03-20 | 2003-12-30 | Comar, Inc. | Rotatable compact case with non-removable pill package insert |
WO2002098495A1 (en) | 2001-06-07 | 2002-12-12 | Innovata Biomed Limited | Unit dosage powder container |
US8061006B2 (en) | 2001-07-26 | 2011-11-22 | Powderject Research Limited | Particle cassette, method and kit therefor |
US20080300535A1 (en) * | 2001-07-26 | 2008-12-04 | Powderject Research Limited | Particle cassette, method and kit therefor |
US6871647B2 (en) | 2001-09-19 | 2005-03-29 | Advent Pharmaceuticals Pty Ltd | Inhaler |
US7931022B2 (en) * | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
US20030075172A1 (en) * | 2001-10-19 | 2003-04-24 | Johnson Keith A. | Method and apparatus for dispensing inhalator medicament |
US9636471B2 (en) | 2002-01-25 | 2017-05-02 | Glaxo Group Limited | Medicament dispenser |
US20050154491A1 (en) * | 2002-01-25 | 2005-07-14 | Anderson Gregor J.M. | Medicament dispenser |
US8511304B2 (en) | 2002-01-25 | 2013-08-20 | Glaxo Group Limited | Medicament dispenser |
US20060187750A1 (en) * | 2002-03-01 | 2006-08-24 | Victor Aldrich | Rotary blending apparatus and system |
US20050236420A1 (en) * | 2002-03-06 | 2005-10-27 | Reckitt Benckiser N.V. | Container |
WO2003080469A1 (en) * | 2002-03-19 | 2003-10-02 | Comar, Inc. | Rotatable compact case with non-removable pill package insert |
US20050103678A1 (en) * | 2002-03-26 | 2005-05-19 | Clark Verna L. | Method for forming a laminate assembly and products formed thereby |
US7448184B2 (en) | 2002-03-26 | 2008-11-11 | Glaxo Group Limited | Method for forming a laminate assembly with an ultrasonic welder |
US7271197B2 (en) | 2002-04-25 | 2007-09-18 | Glaxo Group Limited | Phenethanolamine derivatives |
US20050256201A1 (en) * | 2002-04-25 | 2005-11-17 | Glaxo Group Limited | Phenethanolamine derivatives |
US20060050765A1 (en) * | 2002-04-25 | 2006-03-09 | Walker Dwight S | Magnetoacoustic sensor system and associated method for sensing environmental conditions |
US7429127B2 (en) | 2002-04-25 | 2008-09-30 | Glaxo Group Limited | Magnetoacoustic sensor system and associated method for sensing environmental conditions |
US20090165790A1 (en) * | 2002-05-10 | 2009-07-02 | Oriel Therapeutics, Inc. | Dry powder inhalers |
US8210172B2 (en) | 2002-05-10 | 2012-07-03 | Oriel Therapeutics, Inc. | Dry powder inhalers |
US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US6985798B2 (en) | 2002-05-10 | 2006-01-10 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US7520278B2 (en) | 2002-05-10 | 2009-04-21 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US7677411B2 (en) | 2002-05-10 | 2010-03-16 | Oriel Therapeutics, Inc. | Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders |
US20040153262A1 (en) * | 2002-05-10 | 2004-08-05 | Crowder Timothy M. | Dry powder dose filling systems and related methods |
WO2003095010A2 (en) * | 2002-05-10 | 2003-11-20 | Oriel Therapeutics, Inc. | Dry powder inhalers for use with piezoelectric polymer-driven delivery means, and associated blister package comprising a piezoelectric polymer material |
US20040050860A1 (en) * | 2002-05-10 | 2004-03-18 | Crowder Timothy M. | Apparatus, systems and related methods for dispensing and /or evaluating dry powders |
US7118010B2 (en) | 2002-05-10 | 2006-10-10 | Oriel Therapeutics, Inc. | Apparatus, systems and related methods for dispensing and /or evaluating dry powders |
WO2003095010A3 (en) * | 2002-05-10 | 2004-03-18 | Oriel Therapeutics Inc | Dry powder inhalers for use with piezoelectric polymer-driven delivery means, and associated blister package comprising a piezoelectric polymer material |
US7428446B2 (en) | 2002-05-10 | 2008-09-23 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US7089786B2 (en) | 2002-05-15 | 2006-08-15 | Glaxo Group Limited | Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging |
WO2003107397A2 (en) * | 2002-05-15 | 2003-12-24 | Glaxo Group Limited | Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging |
WO2003107397A3 (en) * | 2002-05-15 | 2004-02-26 | Glaxo Group Ltd | Microelectromechanical system and method for determining temperature and moisture profiles within pharmaceutical packaging |
US20050223827A1 (en) * | 2002-05-15 | 2005-10-13 | Walker Dwight S | Microelectromechanical system and method for determning temperature and moisture profiles within pharmaceutical packaging |
US7185651B2 (en) | 2002-06-18 | 2007-03-06 | Nektar Therapeutics | Flow regulator for aerosol drug delivery and methods |
US20040000309A1 (en) * | 2002-06-18 | 2004-01-01 | William Alston | Flow regulator for aerosol drug delivery and methods |
US20050268908A1 (en) * | 2002-07-25 | 2005-12-08 | Bonney Stanley G | Medicament dispenser |
US20050268909A1 (en) * | 2002-07-25 | 2005-12-08 | Bonney Stanley G | Medicament dispenser |
US20050274378A1 (en) * | 2002-07-25 | 2005-12-15 | Bonney Stanley G | Medicament dispenser |
US20050251289A1 (en) * | 2002-07-25 | 2005-11-10 | Bonney Stanley G | Medicament dispenser |
US20050247312A1 (en) * | 2002-07-25 | 2005-11-10 | Davies Michael B | Medicament dispenser |
US20070267318A1 (en) * | 2002-08-29 | 2007-11-22 | Colbert Packaging Corporation | Dispensing Package |
US7784250B2 (en) | 2002-08-29 | 2010-08-31 | Colbert Packaging Corporation | Method of forming childproof blister pack |
US7748535B2 (en) * | 2002-08-29 | 2010-07-06 | Colbert Packaging Corporation | Dispensing package |
US20080223747A1 (en) * | 2002-08-29 | 2008-09-18 | Colbert Packaging Corporation | Childproof, senior-friendly blister pack |
US20070139442A1 (en) * | 2002-09-13 | 2007-06-21 | Robinson Karl E | Coated blending system |
US20060205790A1 (en) * | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
US7442839B2 (en) | 2002-10-28 | 2008-10-28 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
US20060076010A1 (en) * | 2002-12-18 | 2006-04-13 | King Michael L | Drug delivery system with vented mouthpiece |
US20050252510A1 (en) * | 2002-12-18 | 2005-11-17 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
US6941947B2 (en) | 2002-12-18 | 2005-09-13 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
WO2004054646A1 (en) | 2002-12-18 | 2004-07-01 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
US20040118399A1 (en) * | 2002-12-18 | 2004-06-24 | Elan Pharmaceutical Technologies | Unit dose dry powder inhaler |
US20040173211A1 (en) * | 2003-01-14 | 2004-09-09 | Boehringer Ingelheim International Gmbh | Powder inhaler |
US20060148771A1 (en) * | 2003-02-14 | 2006-07-06 | Keith Biggadike | Medicinal compounds |
US7538127B2 (en) | 2003-02-14 | 2009-05-26 | Glaxo Group Limited | Medicinal compounds |
US20090230130A1 (en) * | 2003-06-09 | 2009-09-17 | John Gelardi | System for storing and unpacking encased article |
US20060237010A1 (en) * | 2003-06-16 | 2006-10-26 | Rijksuniversiteit Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
US7617822B2 (en) | 2003-06-16 | 2009-11-17 | Rijksuniversiteit Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
US20090105309A1 (en) * | 2003-10-22 | 2009-04-23 | Glaxo Group Limited | Medicinal Compounds |
US20070135490A1 (en) * | 2003-10-24 | 2007-06-14 | Keith Biggadike | Phenetanolamine derivatives |
US7451761B2 (en) | 2003-10-27 | 2008-11-18 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US7377277B2 (en) | 2003-10-27 | 2008-05-27 | Oriel Therapeutics, Inc. | Blister packages with frames and associated methods of fabricating dry powder drug containment systems |
US20070277820A1 (en) * | 2003-10-27 | 2007-12-06 | Timothy Crowder | Blister packages and associated methods of fabricating dry powder drug containment systems |
US20070053843A1 (en) * | 2003-10-28 | 2007-03-08 | Dawson Michelle L | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
US7294650B2 (en) | 2003-12-17 | 2007-11-13 | Glaxo Group Limited | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders |
US20070172385A1 (en) * | 2003-12-17 | 2007-07-26 | Glaxo Group Limited | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders |
US20050143675A1 (en) * | 2003-12-31 | 2005-06-30 | Home Diagnostics, Inc. | Integrated diagnostic test system |
US20080108645A1 (en) * | 2004-02-11 | 2008-05-08 | Cambridge Laboratories, (Ireland), Ltd. | Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them |
US7159720B2 (en) | 2004-03-18 | 2007-01-09 | Pearson Stephen J | Container having a rotatable ring |
US7846973B2 (en) | 2004-04-02 | 2010-12-07 | Theravance, Inc. | Chemical process and new crystalline form |
US20100063157A1 (en) * | 2004-04-02 | 2010-03-11 | Caine Darren Michael | Chemical process and new crystalline form |
US20050238708A1 (en) * | 2004-04-23 | 2005-10-27 | Andrew Jones | Sealed capsule including an integrated puncturing mechanism |
US7861712B2 (en) | 2004-04-23 | 2011-01-04 | Manta Product Development | Sealed capsule including an integrated puncturing mechanism |
US20060005398A1 (en) * | 2004-07-12 | 2006-01-12 | Steve Sramek | Device for removing a pharmaceutical dosage unit from a unit package |
US20110061652A1 (en) * | 2004-10-21 | 2011-03-17 | Boehringer Ingelheim International Gmbh | Blister for inhalers |
US20080042823A1 (en) * | 2004-11-12 | 2008-02-21 | Heasley Matthew G | Sensor System with Acoustic Transducer |
US20080125462A1 (en) * | 2005-01-11 | 2008-05-29 | Lois Elizabeth Vernon | Cinnamate Salts Of A Beta-2 Adrenergic Agonist |
US20090047351A1 (en) * | 2005-02-10 | 2009-02-19 | Stephen Newman | Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom |
US20090029901A1 (en) * | 2005-02-10 | 2009-01-29 | Marian Wood-Kaczmar | Process for Crystallizing Lactose Particles for Use in Pharmaceutical Formulations |
US9365905B2 (en) | 2005-02-10 | 2016-06-14 | Dmv-Fonterra Excipients Technology Gmbh | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
EP3199164A1 (en) | 2005-02-10 | 2017-08-02 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
US20090057186A1 (en) * | 2005-02-15 | 2009-03-05 | Willard Rick L | Pill packaging system |
EP2436686A1 (en) | 2005-03-25 | 2012-04-04 | Glaxo Group Limited | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator |
WO2006104889A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Novel compounds |
EP2447266A1 (en) | 2005-03-25 | 2012-05-02 | Glaxo Group Limited | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator |
US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
US10047132B2 (en) | 2005-04-29 | 2018-08-14 | Peter C. Dowling | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US8653028B2 (en) | 2005-04-29 | 2014-02-18 | Rui Rong Yuan | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US10010583B2 (en) | 2005-04-29 | 2018-07-03 | Peter C. Dowling | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
US20110190217A1 (en) * | 2005-04-29 | 2011-08-04 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides |
US20090029906A1 (en) * | 2005-04-29 | 2009-01-29 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US9765128B2 (en) | 2005-04-29 | 2017-09-19 | Peter C. Dowling | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US11559565B2 (en) | 2005-04-29 | 2023-01-24 | United States Government As Represented By The Department Of Veterans Affairs | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
US9585932B2 (en) | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
US20080319000A1 (en) * | 2005-07-14 | 2008-12-25 | Cambridge Laboratories (Ireland) Limited | Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease |
US20080197045A1 (en) * | 2005-07-27 | 2008-08-21 | Burkhard Metzger | Medicament Blister |
US9168342B2 (en) * | 2005-07-27 | 2015-10-27 | Boehringer Ingelheim International Gmbh | Medicament blister |
US20090275605A1 (en) * | 2005-08-05 | 2009-11-05 | Cambridge Laboratories (Ireland) Limited | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease |
US20090192227A1 (en) * | 2005-08-24 | 2009-07-30 | Rabindra Tirouvanziam | N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease |
US20070049641A1 (en) * | 2005-08-24 | 2007-03-01 | Rabindra Tirouvanziam | Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis |
US20090291894A1 (en) * | 2005-09-07 | 2009-11-26 | Nikolaos Tezapsidis | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
US20100113358A1 (en) * | 2005-09-07 | 2010-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
US8642543B2 (en) | 2005-09-07 | 2014-02-04 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
US20070066527A1 (en) * | 2005-09-07 | 2007-03-22 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US7891100B2 (en) | 2006-01-03 | 2011-02-22 | Meadwestvaco Corporation | System for opening an article encasement |
US20070164029A1 (en) * | 2006-01-03 | 2007-07-19 | Gelardi John A | System for Opening an Article Encasement |
US20090194105A1 (en) * | 2006-04-13 | 2009-08-06 | Jens Besseler | Inhaler |
US8584669B2 (en) * | 2006-04-13 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhaler |
WO2008037519A1 (en) * | 2006-09-26 | 2008-04-03 | Alfred Von Schuckmann | Dispenser for powder compounds |
EP2100634A3 (en) * | 2006-09-26 | 2009-09-23 | von Schuckmann, Alfred | Dispenser for powder compounds |
EP2100634A2 (en) | 2006-09-26 | 2009-09-16 | von Schuckmann, Alfred | Dispenser for powder compounds |
US8434476B2 (en) * | 2006-09-26 | 2013-05-07 | Alfred Von Schuckmann | Dispenser for pulverulent substances |
US20100083962A1 (en) * | 2006-09-26 | 2010-04-08 | Alfred Von Schuckmann | Dispenser for pulverulent substances |
US20080156816A1 (en) * | 2007-01-03 | 2008-07-03 | Gelardi John A | Container With Cutting Apparatus |
US20090196927A1 (en) * | 2007-01-10 | 2009-08-06 | Alyssa Panitch | Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor |
US9447158B2 (en) | 2007-01-10 | 2016-09-20 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
US20100098760A1 (en) * | 2007-01-10 | 2010-04-22 | Alyssa Panitch | Polypeptide for treating or preventing adhesions |
US8536303B2 (en) | 2007-01-10 | 2013-09-17 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
US20090149389A1 (en) * | 2007-01-10 | 2009-06-11 | Purdue Research Foundation | Kinase Inhibitors And Uses Thereof |
US8741849B2 (en) | 2007-01-10 | 2014-06-03 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
US9649354B2 (en) | 2007-01-10 | 2017-05-16 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therfor |
US9034815B2 (en) | 2007-01-10 | 2015-05-19 | Moerae Matrix, Inc | Polypeptide for treating or preventing adhesions |
US9493508B2 (en) | 2007-01-10 | 2016-11-15 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
WO2008118724A1 (en) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides as ikk2 inhibitors |
US20080237082A1 (en) * | 2007-03-29 | 2008-10-02 | R. P. Scherer Technologies, Inc. | Child resistant device for housing blister packs |
WO2009004456A1 (en) * | 2007-07-02 | 2009-01-08 | Pfizer Limited | Dry powder container and use of such dry powder container in a dry powder inhaler |
CN101945682A (en) * | 2008-02-12 | 2011-01-12 | 阿斯利康(瑞典)有限公司 | Inhaler comprising a base having at least one sealed cavity containing medicament |
US9174011B2 (en) | 2008-02-12 | 2015-11-03 | Astrazeneca Ab | Inhaler comprising a base having a plurality of medicament containing sealed cavities |
CN101945682B (en) * | 2008-02-12 | 2013-12-04 | 阿斯利康(瑞典)有限公司 | Inhaler comprising a base having at least one sealed cavity containing medicament |
US20110190333A1 (en) * | 2008-06-13 | 2011-08-04 | Biovail Laboratories International (Barbados) S.R.L. | Dihydrotetrabenanzine for the treatment of anxiety |
US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
US20100055133A1 (en) * | 2008-08-12 | 2010-03-04 | Biovail Laboratories International (Barbados) S.R.L | Pharmaceutical compositions |
US20100087476A1 (en) * | 2008-09-08 | 2010-04-08 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compounds |
US20100087475A1 (en) * | 2008-09-08 | 2010-04-08 | Biovali Laboratories International (Barbados) S.R.L. | Pharmaceutical compounds |
US7956065B2 (en) | 2008-09-08 | 2011-06-07 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compounds |
US8671938B2 (en) | 2008-09-26 | 2014-03-18 | Oriel Therapeutics, Inc. | Inhalers with airway disks having discrete airway channels and related disks and methods |
US8381721B2 (en) | 2008-09-26 | 2013-02-26 | Oriel Therapeutics, Inc. | Dry powder inhalers with dual piercing members and related devices and methods |
US20100078022A1 (en) * | 2008-09-26 | 2010-04-01 | Rachel Striebig | Inhalers with airway disks having discrete airway channels and related disks and methods |
US9597465B2 (en) | 2008-09-26 | 2017-03-21 | Oriel Therapeutics, Inc. | Methods of operating and fabricating inhalers with airway disks having discrete airway channels |
US9795749B2 (en) | 2008-09-26 | 2017-10-24 | Oriel Therapeutics, Inc. | Dry powder inhalers with dual piercing members and methods of operating same |
US8550071B2 (en) | 2008-09-26 | 2013-10-08 | Oriel Therapeutics, Inc. | Inhalers with airway disks having discrete airway channels and related disks and methods |
US20110162648A1 (en) * | 2008-09-26 | 2011-07-07 | Ruckdeschel Thomas W | Inhaler mechanisms with radially biased piercers and related methods |
WO2010036839A2 (en) * | 2008-09-26 | 2010-04-01 | Oriel Therapeutics, Inc. | Inhalers with airway disks having discrete airway channels and related disks and methods |
US8985103B2 (en) | 2008-09-26 | 2015-03-24 | Oriel Therapeutics, Inc. | Dry powder inhalers with dual piercing members |
US10493222B2 (en) | 2008-09-26 | 2019-12-03 | Oriel Therapeutics, Inc. | Dry powder dose container assemblies and related inhalers |
US8887722B2 (en) | 2008-09-26 | 2014-11-18 | Oriel Therapeutics, Inc. | Inhaler mechanisms with radially biased piercers and related methods |
WO2010036839A3 (en) * | 2008-09-26 | 2010-06-03 | Oriel Therapeutics, Inc. | Inhalers with airway disks having discrete airway channels and related disks and methods |
US9050427B2 (en) | 2008-09-30 | 2015-06-09 | Oriel Therapeutics, Inc. | Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods |
US20110174306A1 (en) * | 2008-09-30 | 2011-07-21 | David Harris | Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods |
US20110186047A1 (en) * | 2008-10-01 | 2011-08-04 | Scott Alexander Lewis | Dry Powder Inhalers with Rotating Piercing Mechanisms and Related Devices and Methods |
US8646446B2 (en) | 2008-10-01 | 2014-02-11 | Oriel Therapeutics, Inc. | Dry powder inhalers with rotating piercing mechanisms and related devices and methods |
US9327008B2 (en) | 2008-12-10 | 2016-05-03 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
US20100158968A1 (en) * | 2008-12-10 | 2010-06-24 | Alyssa Panitch | Cell-permeant peptide-based inhibitor of kinases |
US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
EP3202399A1 (en) | 2009-07-24 | 2017-08-09 | Amazetis SA | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US20110052658A1 (en) * | 2009-07-27 | 2011-03-03 | Alyssa Panitch | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
USD685461S1 (en) | 2010-03-26 | 2013-07-02 | Oriel Therapeutics, Inc. | Dose disk for a dry powder inhaler |
USD635246S1 (en) | 2010-03-26 | 2011-03-29 | Oriel Therapeutics, Inc. | Dose disk for dry powder inhalers |
USD711528S1 (en) | 2010-03-26 | 2014-08-19 | Oriel Therapeutics, Inc. | Dry powder inhaler |
USD745660S1 (en) | 2010-03-26 | 2015-12-15 | Oriel Therapeutics, Inc. | Dry powder inhaler |
USD641076S1 (en) | 2010-03-26 | 2011-07-05 | Oriel Therapeutics, Inc. | Dry powder inhaler |
USD684684S1 (en) | 2010-03-26 | 2013-06-18 | Oriel Therapeutics, Inc. | Dry powder inhaler |
US20110272427A1 (en) * | 2010-05-07 | 2011-11-10 | Fily Sebastien Lucien | Blister dispenser |
WO2012028663A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2954888A1 (en) | 2010-08-31 | 2015-12-16 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012028662A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
US9297813B2 (en) | 2010-11-11 | 2016-03-29 | Agency For Science, Technology And Research | Targeting metabolic enzymes in human cancer |
US20120241451A1 (en) * | 2011-03-24 | 2012-09-27 | Fred Pether | Tamper Device |
US8579116B2 (en) * | 2011-03-24 | 2013-11-12 | Oneworld Design and Manufacturing Group, Ltd. | Tamper evident device |
US10562947B2 (en) | 2011-04-12 | 2020-02-18 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
US9642888B2 (en) | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
WO2012159103A1 (en) | 2011-05-19 | 2012-11-22 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
CN102303772A (en) * | 2011-06-22 | 2012-01-04 | 美的集团有限公司 | Automatic adding device for household appliance |
CN102303772B (en) * | 2011-06-22 | 2013-05-08 | 美的集团股份有限公司 | Automatic adding device for household appliance |
EP2589381A1 (en) | 2011-11-04 | 2013-05-08 | Rabindra Tirouvanziam | Compositions for improving or preserving lung function in a patient with a pulmonary disorder |
US10034839B2 (en) | 2012-03-09 | 2018-07-31 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
US9452218B2 (en) | 2012-03-09 | 2016-09-27 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
US9493291B2 (en) | 2012-06-29 | 2016-11-15 | R. J. Reynolds Tobacco Company | Dispensing container, packaged product assembly, and related method |
US9108784B2 (en) * | 2012-06-29 | 2015-08-18 | R.J. Reynolds Tobacco Company | Dispensing container, packaged product assembly, and related method |
US20140001194A1 (en) * | 2012-06-29 | 2014-01-02 | R. J. Reynolds Tobacco Company | Dispensing container, packaged product assembly, and related method |
US11291644B2 (en) | 2012-09-04 | 2022-04-05 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
WO2014039533A2 (en) | 2012-09-04 | 2014-03-13 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
WO2014085474A1 (en) | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
US8875892B1 (en) | 2013-03-11 | 2014-11-04 | Dominique Warner | Multi-compartment ring-shaped holder |
WO2015038644A2 (en) | 2013-09-10 | 2015-03-19 | Debrabander Jef | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
US9856233B2 (en) | 2013-09-10 | 2018-01-02 | Board Of Regents Of The University Of Texas System | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins |
US10577344B2 (en) | 2013-09-10 | 2020-03-03 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins |
EA034279B1 (en) * | 2013-12-23 | 2020-01-24 | Гленмарк Фармасьютикалс Лтд | Dry powder inhaler |
WO2015097662A1 (en) * | 2013-12-23 | 2015-07-02 | Glenmark Pharmaceuticals Ltd | A dry powder inhaler |
US10336788B2 (en) | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
WO2016081475A1 (en) | 2014-11-17 | 2016-05-26 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
US10500249B2 (en) | 2014-11-17 | 2019-12-10 | Moerae Matrix Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
US11357840B2 (en) | 2014-12-10 | 2022-06-14 | Hyperstem Sa | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
US10688167B2 (en) | 2014-12-10 | 2020-06-23 | Hyperstem Sa | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
WO2016092378A1 (en) | 2014-12-10 | 2016-06-16 | Angelo Luigi Vescovi | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors |
USD857650S1 (en) | 2014-12-16 | 2019-08-27 | Muzik Inc. | Touchpad |
USD793356S1 (en) * | 2014-12-16 | 2017-08-01 | Musik, LLC | Headphone touchpad |
US10087225B2 (en) | 2015-01-08 | 2018-10-02 | Moerae Matrix, Inc. | Formulation of MK2 inhibitor peptides |
WO2016142426A1 (en) | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
US9999655B2 (en) | 2015-03-12 | 2018-06-19 | Moerae Matrix, Inc. | Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
WO2016200694A1 (en) | 2015-06-10 | 2016-12-15 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
EP3766878A1 (en) | 2015-06-15 | 2021-01-20 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
EP3782996A1 (en) | 2015-06-15 | 2021-02-24 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
WO2016203400A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
US11548894B2 (en) | 2015-07-06 | 2023-01-10 | The Board Of Regents Of The University Of Texas System | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers |
US10112948B2 (en) | 2015-07-06 | 2018-10-30 | The Board Of Regents Of The University Of Texas System | Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers |
WO2017011215A1 (en) | 2015-07-15 | 2017-01-19 | The Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
US20180236188A1 (en) * | 2015-10-23 | 2018-08-23 | Arven Ilac Sanayi Ve Ticaret A.S. | Blister for inhalable formulation of tiotropium bromide |
US11833118B2 (en) | 2016-01-20 | 2023-12-05 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
US10328216B2 (en) | 2016-01-20 | 2019-06-25 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation |
WO2018055524A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
WO2018055526A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
WO2018055527A1 (en) | 2016-09-20 | 2018-03-29 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists |
WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
WO2018109648A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
WO2018109646A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 compounds |
WO2018109649A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as nrf2 regulators |
WO2018200425A1 (en) | 2017-04-24 | 2018-11-01 | Cocrystal Pharma, Inc. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
US11014941B2 (en) | 2017-04-24 | 2021-05-25 | Cocrystal Pharma, Inc. | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
WO2019116230A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
WO2019115640A1 (en) | 2017-12-15 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | 6-(morpholin-4-yl)-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine derivatives as m-tor inhibitors |
WO2019141694A1 (en) | 2018-01-17 | 2019-07-25 | Glaxosmithkline Intellectual Property Development Limited | Pi4kiiibeta inhibitors |
WO2019224667A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Indanes as nrf2 activators |
WO2020023813A1 (en) | 2018-07-27 | 2020-01-30 | Cocrystal Pharma, Inc. | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |
WO2020055858A1 (en) | 2018-09-10 | 2020-03-19 | Cocrystal Pharma, Inc. | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication |
WO2020081751A1 (en) | 2018-10-17 | 2020-04-23 | Cocrystal Pharma, Inc. | Combinations of inhibitors of influenza virus replication |
WO2020102270A1 (en) | 2018-11-13 | 2020-05-22 | Cocrystal Pharma, Inc. | Formulations of influenza therapeutics |
WO2020112716A1 (en) | 2018-11-26 | 2020-06-04 | Cocrystal Pharma, Inc. | Inhibitors of influenza virus replication |
WO2020249652A1 (en) | 2019-06-13 | 2020-12-17 | Glaxosmithkline Intellectual Property Development Limited | Pyridyl or pyrimidyl mtor kinase inhibitors |
WO2021188620A1 (en) | 2020-03-17 | 2021-09-23 | Cocrystal Pharma Inc. | Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication |
WO2021206876A1 (en) | 2020-04-10 | 2021-10-14 | Cocrystal Pharma, Inc. | Inhibitors of norovirus and coronavirus replication |
WO2021216547A1 (en) | 2020-04-20 | 2021-10-28 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
WO2022179967A1 (en) | 2021-02-23 | 2022-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Vadadustat for treating covid-19 in a hospitalized subject |
WO2023014758A1 (en) | 2021-08-03 | 2023-02-09 | Cocrystal Pharma, Inc. | Inhibitors for coronaviruses |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4778054A (en) | Pack for administering medicaments to patients | |
US4627432A (en) | Devices for administering medicaments to patients | |
GB2169265A (en) | Pack for medicament | |
JP4044620B2 (en) | System for administration by inhalation of powdered drugs | |
EP0835147B1 (en) | Dry powder inhaler delivery system | |
EP0883414B1 (en) | Inhalation device | |
FI88112B (en) | ANORDNING FOER ADMINISTRERING AV LAEKEMEDEL TILL PATIENTER | |
EP0469814A1 (en) | Medicament administering devices | |
EP0481666A1 (en) | Powder inhaler device | |
EP2731571B1 (en) | Improvements relating to delivery devices | |
JPH08501046A (en) | Drug packaging | |
JPS5988158A (en) | Apparatus for dosing drug to patient and pack used therefor | |
CA1236736A (en) | Device for administering medicament to patients | |
WO2005110519A1 (en) | Dry powder inhaler | |
FI81255C (en) | Packaging for use in inhalation device | |
IE873338L (en) | Medicament- containing pack. | |
DK173079B1 (en) | Hand-held inhaler for powder or liq. medical inhalants - which are in dose sized blisters of circular disc blister pack | |
NL193681C (en) | Packaging for medicines. | |
MXPA99005698A (en) | Medicament delivery and packaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLAXO GROUP LIMITED, CLARGES HOUSE, 6/12 CLARGES S Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:NEWELL, ROBERT E.;FITZSIMMONS, ROBERT A.;REEL/FRAME:004638/0977;SIGNING DATES FROM 19861103 TO 19861113 Owner name: GLAXO GROUP LIMITED,ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEWELL, ROBERT E.;FITZSIMMONS, ROBERT A.;SIGNING DATES FROM 19861103 TO 19861113;REEL/FRAME:004638/0977 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |